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Abstract
Background: Several factors are believed to influence the development and experience of pain.
Human clinical pain models are central tools, in the investigation of basic physiologic pain responses, and can be
applied in patients as well as in healthy volunteers. Each clinical pain model investigates different aspects of the
human pain response.
Brief thermal sensitization induces a mild burn injury, resulting in development of primary hyperalgesia at the site
of stimulation, and secondary hyperalgesia surrounding the site of stimulation. Central sensitization is believed to
play an important role in the development of secondary hyperalgesia; however, a possible association of secondary
hyperalgesia following brief thermal sensitization and other heat pain models remains unknown. Our aim with this
study is to investigate how close the heat pain detection threshold is associated with the size of the area of
secondary hyperalgesia induced by the clinical heat pain model: Brief thermal sensitization.
Methods and design: We aim to include 120 healthy participants. The participants will be tested on two separate
study days with the following procedures: i) Brief thermal sensitization, ii) heat pain detection threshold and iii) pain
during thermal stimulation. Additionally, the participants will be tested with the Pain Catastrophizing Scale and
Hospital Anxiety and Depression Scale questionnaires.
We conducted statistical simulations based on data from our previous study, to estimate an empirical power of 99.
9 % with α of 0.05. We define that an R2 < 0.25 and predictive intervals larger than +/−150 cm2 are indications of a
weak association.
Discussion: The area of secondary hyperalgesia may serve as a quantitative measure of the central sensitization
induced by cutaneous heat stimulation, and thus may be a biomarker of an individual’s pain sensitivity. The number
of studies investigating secondary hyperalgesia is growing; however basic knowledge of the physiologic aspects of
secondary hyperalgesia in humans is still incomplete. We therefore find it interesting to investigate if HPDT, a
known quantitative sensory test, is associated with areas of secondary hyperalgesia following brief thermal
sensitization
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Background
Psychology, physiology, ethnicity, sex and psychosocial
background are just some of the factors believed to
contribute to the pain experience in the individual.
However, the knowledge of the individual mechanisms
responsible for the development of acute and chronic
pain is still incomplete [1].
Human clinical pain models are central tools, in the in-
vestigation of basic physiologic pain responses, and can be
applied in patients as well as in healthy volunteers [2, 3].
With the pain model brief thermal sensitization (BTS),
the skin is heated to 45 °C for 3 min. resulting in the de-
velopment of primary hyperalgesia at the site of stimula-
tion, and secondary hyperalgesia surrounding the site of
stimulation [4–8]. The area of secondary hyperalgesia is
characterised by reduced thresholds for mechanical
stimulation, and the size of the area can be quantified by
monofilament stimulation. Current evidence indicates
that the development of secondary hyperalgesia to punc-
tate mechanical stimuli following a standardised injury is
caused by central changes in response to a conditioning
stimulus and transmitted by A-delta fibers [1, 9–11].
The secondary hyperalgesia elicited by a clinical pain
model may thus be a result of central sensitization. Cen-
tral sensitization reflects a functional change in the
neuron properties by increased synaptic efficacy and
membrane excitability as well as decreased synaptic in-
hibition [1, 9]. This functional change in the neurons
and nociceptive pathways results in pain threshold re-
duction, increased response to noxious stimulation,
and prolonged duration of pain following noxious
stimulation [1, 9]. Central sensitization encompasses
both an early and late phase, with the early phase in-
dependent of transcription and the late long-lasting
phase transcription dependent [9]. The transcription
dependent long lasting phase of central sensitization
is believed to play an important role in several differ-
ent pain conditions and syndromes, e.g. osteoarthritis
and fibromyalgia [1, 9, 12, 13].
Secondary hyperalgesia following clinical pain models
has been demonstrated to be a robust phenomenon, and
can be applied when investigating basic pain physiology
in humans [4–8, 14–30].
Recently, a meta-analysis [24] of 10 studies (9 pub-
lished) [4–6, 8, 19, 21, 23, 26, 30] indicated that healthy
volunteers had; (I), a large inter-individual variation with
regard to the magnitude of the area of secondary hyper-
algesia after exposure to identical pain stimuli. (II), that
areas of secondary hyperalgesia may be an identifiable
phenotypic indicator and that (III), they may be
predictive of individual pain responses. Furthermore, in
a recently published study [31], results have indicated
that increasing heat pain detection threshold (HPDT)
may be associated with decreasing size of the area of
secondary hyperalgesia. However, the study indicates
that HPDT only offers a very modest explanation of the
variation in the area of secondary hyperalgesia following
standardised burn injury, suggesting that HPDT and sec-
ondary hyperalgesia may be two different pain entities.
Moreover, one recent study found indications of struc-
tural cerebral differences and differences in neuronal ac-
tivation to noxious stimulation, in healthy volunteers
with a large vs. small area of secondary hyperalgesia fol-
lowing a first degree burn injury [25]. Finally, the study
also found suggestions of an association between large
areas of secondary hyperalgesia and high anxiety scores.
The different physiologic properties of BTS and HPDT
[1, 9–11, 32] suggests that they may be two different
pain entities; however the current evidence on the basic
physiologic properties of the areas of secondary hyper-
algesia in humans remains incomplete. The predictive
value of HPDT on postoperative pain [33–35], suggests
that HPDT may partly provide insight on an individual’s
pain sensitivity; however, our previous results indicate
that HPDT and the development of secondary hyper-
algesia may only be weakly associated. This result chal-
lenges the current assumption that areas of secondary
hyperalgesia may be a marker for an individual’s central
sensitization and ultimately the pain sensitivity. This ra-
ther surprising result needs to be explored further. A
thorough evaluation of the basic physiologic properties
in the development of secondary hyperalgesia following
BTS is necessary in order to exploit the full potential of
this clinical pain model, and may provide novel insight
in the development of acute and chronic pain.
In this prospective cohort study we therefore aim to
investigate how close the HPDT, evaluated on two separ-
ate study days, is associated with the size of the area of
secondary hyperalgesia induced by BTS. We hypothesise
that HPDT and area of secondary hyperalgesia are
two predominantly independent entities, and thus, are
weakly associated.
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Methods/design
The method and design of this study is based upon a
previous study by our own research group [31]. The
recruiting of study participants and commencement of
the study was initiated on October 1, 2015.
Study participants
Only healthy male volunteers will be included in the
study. The investigator will provide the study partici-
pants with written and oral information about the study,
as well as information concerning possible risk and side
effects. The study participants will sign a written in-
formed consent, and will receive EUR 20 (USD 27) per
hour for their participation in the study. Inclusion and
exclusion criteria are presented in Table 1.
Setting
The study is conducted in a quiet secluded room
(temperature: 22–25 °C), where only the study partici-
pant and the investigator will be present. The study par-
ticipants will be in a supine position, lying on their back,
during the assessments. The study will be conducted at
the Department of Anaesthesiology, 4231, Rigshospitalet,
Copenhagen, Denmark.
Study design
The study is a confirmatory study designed to investigate
the association between area of secondary hyperalgesia
and HPDT. The study consists of a screening/informa-
tion day and two study days. To prevent carry-over ef-
fects of the applied tests, the screening day and each of
the two study days must be separated with a minimum
of seven days. The aim with our study is to investigate
the association between HPDT and area of secondary
hyperalgesia, thus the order of the stimulations (HPDT
and BTS) is randomised for each participant for each
study day. Pain during 1 min. thermal stimulation (p-TS)
is conducted subsequent to BTS and HPDT. Likewise, in
order to adjust for possible carry-over effects between
HPDT and BTS we conduct experimental pain testing
on two separate study days with the experimental pain
testing sequence randomised for each study day (see
Randomisation, allocation concealment and blinding).
The study participants will thus be tested with three
types of clinical pain models on two separate study
days. The following clinical pain models will be ap-
plied: Brief thermal sensitization (BTS), heat pain de-
tection threshold (HPDT) and pain during thermal
stimulation (p-TS) (see Assessments and tests). Fur-
thermore, the study participants will complete the
two psychological tests, Pain Catastrophizing Scale
(PCS) and Hospital Anxiety and Depression Scale
(HADS) (see Assessments and tests).
The screening day and the two identical study days
will proceed as follows:
Screening day:
 Oral information regarding the study is delivered by
the primary investigator. Informed consent and
written authority will be handed out for the
participant to sign. The participant will be given
time to consider the information.
 Short medical history by the primary investigator.
Thorough screening of in- and exclusion criteria.
Measurement of height, weight, blood pressure
and pulse.
 In order to familiarise the study participant with
the types of pain conditioning, the 3 types of pain
conditioning test are presented and performed on
the study participant.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years and ≤35 years Study participants who cannot cooperate to the test.
Speak and understand the Danish
language
Study participants who have a weekly intake of >21 units of alcohol, or a have consumed >3 units of alcohol
within 24 h before study day.
Healthy male Study participants with a substance abuse, assessed by the investigator.
Signed informed consent Study participants, who have consumed analgesics less than 3 days before study day.
Study participants, who have consumed antihistamines less than 48 h before study day.
Study participants who have consumed antidepressant medication during the last 30 days before the study
Study participants who have consumed prescription medicine during the last 30 days before the study.
Study participants with neurological illnesses.
Study participants with chronic pain
Study participants with psychiatric diagnoses
Study participants with tattoos on the extremities
Study participants with eczema, wounds or sunburns on the sites of stimulation.
Study participants with a Body Mass Index of >30 kg/m2 or <18 kg/m2
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 Distribution of PCS and HADS (in Danish), together
with an opaque envelope, in which the answered
tests are to be put, and a sealed envelope will be
returned to the primary investigator on the first
study day.
 Potentially clarifying questions concerning the study
or PCS and HADS are answered.
Study day 1 and 2:
 Inspection of signed informed consent and written
authority.
 Study day 1: Hand in of PCS and HADS in an
opaque sealed envelope. The envelope is first opened
when all study participants have completed study
day 1 and 2.
 The study participant is placed on a bed in the
supine position.
 The timeline of tests performed will be as follows:
○ Commencement of study 0 min: BTS or HPDT
(depending on randomisation)
○ At 7 min: BTS or HPDT (depending on
randomisation)
○ At 10 min: p-TS
Assessment and tests
Brief thermal sensitization (BTS)
A computer-controlled thermode (Somedic MSA Ther-
motester™; size 2.5 × 5 cm) is placed on the participant’s
skin. The initial temperature of the thermode is 32 °C,
and temperature is increased 1 °C/s until it reaches 45 °
C. The temperature of the thermode remains 45 °C for
3 min., and while the thermode still has contact with the
skin, and has a temperature of 45 °C, the assessment of
secondary hyperalgesia is conducted. The assessment of
secondary hyperalgesia will approximately take 1–2 min,
with a maximum duration of heat stimulation of 5 min.
The test is conducted centrally on the anterior part of
the right thigh.
Assessment of secondary hyperalgesia
The area of secondary hyperalgesia is quantified after
stimulation with a 19G monofilament (von Frey hair) in
4 linear paths arranged in 90° around the centre of
stimulation. Stimulation will begin 15 cm. from the
centre of stimulation and advance in steps of 5 mm. with
1 s intervals towards the centre of stimulation. When
the participant states a clear change in sensation (intense
pricking, burning, tenderness) the place will be marked
with a felt pen and the transverse and longitudinal axes
will be measured with a pliable measuring tape for later
rectangular area calculation.
Heat pain detection threshold (HPDT)
Heat pain detection threshold represents the lowest
temperature that is perceived as painful, when heating
the skin with the computer-controlled thermode. The
initial temperature is 32 °C, and temperature is increased
1 °C/s. The participant is asked to press a button when
the heat is perceived as painful. If 52 °C (the maximum
temperature for the thermode) is reached before the par-
ticipant’s threshold has been registered, the thermode
will automatically return to the initial temperature of
32 °C to prevent excessive tissue damage. The HPDT is
calculated as an average of four stimulations. Each
stimulation will be performed with an interval of 6–10 s.
The test is conducted centrally on the anterior part of
the dominant lower arm.
Pain during thermal stimulation (p-TS)
The computer-controlled thermode is placed on the par-
ticipant’s skin. The initial temperature of the thermode
is 32 °C, and temperature is increased 1 °C/s until it
reaches 45 °C, where it remains for 1 min. During this
the participant evaluates the pain with an electronic
VAS-scale. The participant will continuously evaluate
the pain using the electronic VAS-scale because of the
fluctuations in pain intensity during this type of stimula-
tion. The equipment (Somedic USB-VAS) automatically
calculates a VAS-score under the curve (VAS-AUC) and
a maximum VAS-score for the time period. The partici-
pant will not be able to see the computer screen during
the measurement, and each pain evaluation will be
independent of the previous evaluation. The test is con-
ducted centrally on the anterior part of the non-
dominant lower arm.
Pain assessment
Visual analogue scale (VAS), index from 0–100 mm,
where 0 mm represents “no pain”, and 100 mm repre-
sents “the worst pain imaginable”.
Hospital Anxiety and Depression Scale (HADS)
HADS is a questionnaire consisting of 14 questions, and
is a four-point Likert scale with values from 0–3. HADS
can be subdivided into HADS-A, evaluating anxiety, and
HADS-D, evaluating depression. The highest achievable
score is 42, and a total HADS-score will estimate the
participant’s level of distress. To evaluate anxiety and
depression separately, HADS-A and HADS-D must be
evaluated separately, with a maximum score of 21 in the
two subtests.
The interpretation of the score in HADS-A and
HADS-D is as follows:
– 0–7: Normal
– 8: Mild level of anxiety/depression
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– 11–15: Moderate level of anxiety/depression
– ≥16: Severe level of anxiety/depression
The HADS questionnaire is to be completed before
study day 1.
Pain Catastrophizing Scale (PCS)
PCS is a questionnaire consisting of 13 questions. PCS is
a five-point Likert scale with values from 0–4, and can
be subdivided into 3 subtests, that each evaluates the
central elements in catastrophizing: Rumination, magni-
fication and helplessness. The highest achievable score is
52, and with separate evaluation of the three subtests,
the three different elements can be assessed individually.
To evaluate the three elements separately the 13 ques-
tions must be evaluated in the three following
subgroups:
– Rumination: The sum of question 8, 9, 10, 11.
Maximal sum =16
– Magnification: The sum of question 6, 7, 13.
Maximal sum = 12
– Helplessness: The sum of question 1, 2, 3, 4, 5, 12.
Maximal sum = 24
The PCS questionnaire is to be completed before
study day 1.
Randomisation, allocation concealment and blinding
The three types of clinical pain models consist of
BTS, HPDT, and p-TS (see Assessments and tests).
p-TS are conducted subsequent to BTS and HPDT.
The order of BTS and HPDT is randomised, by a
random allocation sequence, computer-generated by
Copenhagen Trial Unit and stored in sealed and
opaque envelopes to secure adequate allocation
concealment.
Completed psychological tests will be kept in opaque
sealed envelopes. The blinding will be broken when all
volunteers have completed the two study days.
Outcomes
Primary outcome
How close is the heat pain detection threshold associ-
ated with the size of the area of secondary hyperalgesia
induced by BTS? The association will be expressed in R2
and with prediction intervals for the area of BTS given
fixed values of HPDT.
Secondary outcomes
To investigate:
1. How close the VAS-AUC following p-TS is associ-
ated with the size of the area of secondary hyper-
algesia induced by BTS.
2. How close the Max VAS-score following p-TS is as-
sociated with the size of the area of secondary
hyperalgesia induced by BTS.
3. How close the score of PCS is associated with the
size of the area of secondary hyperalgesia induced
by BTS.
4. How close the score of HADS is associated with
the size of the area of secondary hyperalgesia
induced by BTS.
5. How close the subscales in the two psychological
tests (PCS-rumination, PCS-magnification, PCS-
helplessness, and HADS-Anxiety, HADS-Depression)
are associated with the size of the area of secondary
hyperalgesia.
Hypothesis
Our hypothesis is that HPDT and area of secondary
hyperalgesia elicited by BTS are two predominantly
independent entities, and that the area of secondary
hyperalgesia is poorly explained by HPDT. We will take
R2 < 0.25 and predictive intervals larger than +/−150 cm2
as indications of a weak association.
Simulation based assessment of sample size
Simulation based power calculations are based on data
from our own previous study [31]. In particular power
calculations are based on a linear relationship between
BTS and HPDT derived from inference of data from this
previous study.
With α of 0.05 and 120 participants we estimated an
empirical power of over 99.9 % using simulations. This
provides adequate power to confirm if heat pain
detection threshold and area of secondary hyperalgesia
following BTS are to large extent independent entities,
and thus weakly associated.
Please see the online available Additional file 1
(intrep3-ver3-2015) for the full simulation study.
Data analysis plan
Plan of statistical analysis of primary outcome
The association of HPDT with the area of secondary
hyperalgesia will be investigated by linear regression on
the estimated best linear unbiased predictors (EBLUPS)
of the individual area of secondary hyperalgesia. The in-
dividual area of secondary hyperalgesia will be adjusted
with the body surface area of the individual participant.
Significance of the predictor will be assessed by ANOVA
methods. The ability of the HPDT to predict individual
variations in areas of secondary hyperalgesia will be in-
vestigated by linear regression on the EBLUPS of the in-
dividual area of secondary hyperalgesia. Significance of
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the predictor will be assessed by ANOVA methods and
the predictive ability will be quantified by summary of
prediction error including 95 % prediction interval.
Relevant examples will be presented illustrating how
accurate HPDT predicts secondary hyperalgesia in indi-
vidual patients or vice versa.
Subgroup analyses based will be performed if at least
15% of the study population differs in ethnicity.
Plan of statistical analysis of secondary outcomes
For each of the 5 secondary outcomes the association of
VAS-AUC (following p-TS), Max VAS-score (following
p-TS), PCS, HADS, and subscales of PCS and HADS
with the area of secondary hyperalgesia will be investi-
gated by linear regression on the estimated best linear
unbiased predictors (EBLUPS) of the individual area of
secondary hyperalgesia. Significance of the predictor will
be assessed by ANOVA methods. In case of significance,
the ability of the five variables to predict individual vari-
ations in areas of secondary hyperalgesia will be investi-
gated by linear regression on the EBLUPS of the
individual area of secondary hyperalgesia. Significance of
the predictors will be assessed by ANOVA methods and
their predictive abilities will be quantified by various
summaries of prediction errors including 95 % predic-
tion intervals.
Relevant examples will be presented illustrating how
accurate the five variables predict secondary hyperalgesia
in individual participants or vice versa.
Missing data
For all analyses, an intention-to-test (ITT) analysis will
be performed including all subjects that participated in
the first study day. Analyses will be based on all ob-
served data. If missingness exceeds 5 % and there is indi-
cation of violation of “missing completely at random”
(MCAR) by a statistical significant Littles test, a sensitiv-
ity analysis based on an appropriate model for missing-
ness at random (MAR) or not at random (MNAR) will
be performed.
Statistical significance
All p-values are evaluated at a 5 % significance level. P-
values for multiple comparisons are adjusted for mul-
tiple testing by means of single-step correction [36].
Software
All analyses will be made using the open source statis-
tical programming environment R [37].
Ethics
The applied methods do not cause damage to the skin
or have any other long-term adverse effects. In rare
cases, changes comparable with a first degree sun burn
may appear.
The study will be conducted in accordance with the
principles of the Declaration of Helsinki. Written in-
formed consent will be obtained from all the study partici-
pants. The participants will be aware of the rare possibility
of a first degree burn prior to consenting.
The protocol is approved by the local Danish Research
Ethics Committees (Identifier: H-8-2014-012) and the
Danish Data Protection Agency (Identifier: 30-1436).
The study is also reported on the international database
clinicaltrials.gov (Identifier: NCT02527395).
Discussion
In the present study we aim to investigate how close the
HPDT is associated with the size of the area of second-
ary hyperalgesia induced by BTS. Based on a previous
study [31], we hypothesise that HPDT and area of sec-
ondary hyperalgesia elicited by BTS are two predomin-
antly independent entities, and that the area of
secondary hyperalgesia is poorly explained by HPDT.
We estimate that an R2 < 0.25 and predictive intervals
larger than +/−150 cm2 are indications of a weak associ-
ation. Because we hypothesise that HPDT and the area of
secondary hyperalgesia following BTS are possibly two dif-
ferent pain entities we need a high statistical power to en-
sure that our result is valid. We conducted statistical
simulations with the raw data from our previous study
[31], and have estimated that with 120 participants we
achieve an empirical power of 99.9 %. With an α of 0.05
and an estimated empirical power of almost 100 % we feel
confident that the risk of type 2 error is minimal.
The area of secondary hyperalgesia may serve as a
quantitative measure of the central sensitization induced
by cutaneous heat stimulation, and thus may be a bio-
marker of an individual’s pain sensitivity. The stimuli fol-
lowing HPDT and BTS are transmitted in A-delta and
C-fibres [32].
With 1 °C/s. increase in temperature HPDT primarily ac-
tivates C polymodale nociceptive afferents, and to a lesser
degree A-delta fibres [32]. However, the development of
secondary hyperalgesia to punctate mechanical stimuli is
centrally mediated and occurs as a result of central plasti-
city, and has been demonstrated to involve nerve signals
primarily in A-fiber nociceptors, not C-fibres [1, 9–11].
HPDT has been demonstrated to be highly reproducible,
and may serve as a predictor of pain responses following
surgery [33–35], but the current scientific evidence investi-
gating the predictive value of areas of secondary hyperalge-
sia remains sparse. Thus, if this study demonstrates a weak
association between HPDT and secondary hyperalgesia, it
does not mean that secondary hyperalgesia as a biomarker
for pain sensitivity is useless, just that HPDT and secondary
hyperalgesia following BTS may be two different pain
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entities, and express different aspects of pain physiology.
Studies investigating the value of secondary hyperalgesia in
predicting postoperative pain are warranted in order to
clarify this aspect.
Ethnicity, sex, obesity and hormone cycle are all factors
that may influence pain sensitivity [20, 38–50]. In this study
we aim to investigate the association between HPDT and
secondary hyperalgesia following BTS, and in order to iso-
late a possible association between HPDT and secondary
hyperalgesia we chose to include healthy male volunteers
only. The inclusion of a homogenous male population en-
ables us to focus on the association between HPDT and
secondary hyperalgesia, instead of the influence of the indi-
vidual participant characteristics. This may also be a limita-
tion since the result of the study is primarily applicable in
male volunteers. However, to our knowledge, this is the first
study investigating the association between HPDT and the
area of secondary hyperalgesia following a cutaneous heat
injury, and, thus we need to limit known and unknown var-
iables that may influence the primary outcome and distort
the signal.
Several clinical studies have demonstrated associations
between pain and psychological variables [51–54]; however,
the influence of psychological variables on experimental
pain still remains unclear [55]. In this study we also aim to
investigate a possible association between secondary hyper-
algesia and anxiety, depression and pain catastrophizing.
One study by Salomon et al. [56] demonstrated that a
cognitive-behavioral intervention reducing PCS may reduce
the size of the area secondary hyperalgesia. Salomon et al.
suggests that central sensitization can be modified by inter-
vening and altering the pain-relating thoughts, and, thus
suggests a possible association between the size of second-
ary hyperalgesia areas and PCS.
The number of studies investigating secondary hyper-
algesia as a biomarker for central sensitization and pain
sensitivity is growing; however basic knowledge on the
physiologic aspects of secondary hyperalgesia in humans
is still incomplete. We therefore find it interesting to
investigate if HPDT, a known quantitative sensory test
[57], is associated with areas of secondary hyperalgesia
following BTS.
Additional file
Additional file 1: Simulation study. (PDF 204 kb)
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